Mono and Combination Therapies in Pulmonary Arterial Hypertension Patients with Comorbidities: A COMPERA Analysis
This analysis suggests that PAH patients with comorbidities may benefit more pronounced from combination therapy regarding WHO-FC, BNP/NT-pro-BNP and risk status without a significant difference in survival. Good tolerability is indicated. However, given the relatively younger patient matched subgroup, these findings may not necessarily apply to older patients with a wider range of comorbidities.
Authors
- Ralf Ewert (ORCID: https://orcid.org/0000-0002-6746-9925)
- Marius M. Hoeper (ORCID: https://orcid.org/0000-0001-9086-2293)
- Grzegorz Kopeć (ORCID: https://orcid.org/0000-0001-9921-2801)
- Christine Pausch (ORCID: https://orcid.org/0000-0002-1866-9015)
- Andris Skride (ORCID: https://orcid.org/0000-0002-1087-687X)
- Anton Vonk Noordegraaf (ORCID: https://orcid.org/0000-0002-4057-758X)
- David Pittrow (ORCID: https://orcid.org/0000-0003-1136-2616)
- Matthias Held (ORCID: https://orcid.org/0000-0002-2789-699X)
- Dörte Huscher (ORCID: https://orcid.org/0000-0001-9070-0761)
- Fabian Kreimendahl
- Michael Halank (ORCID: https://orcid.org/0000-0002-9184-4799)
- Stephan Rosenkranz (ORCID: https://orcid.org/0000-0001-6237-1470)
- Marion Delcroix (ORCID: https://orcid.org/0000-0001-8394-9809)
- Hans Klose (ORCID: https://orcid.org/0000-0002-7215-0943)
- Stefan Stadler (ORCID: https://orcid.org/0000-0002-8783-618X)
- Hossein Ardeschir Ghofrani (ORCID: https://orcid.org/0000-0002-2029-4419)
- Dirk Skowasch (ORCID: https://orcid.org/0000-0003-2377-5936)
- Ekkehard Grünig (ORCID: https://orcid.org/0000-0001-7318-3918)
- Stephan Beckmann
- Karen M. Olsson
- Judith Wede
Institutions
- Jagiellonian University (PL)
- University of Bonn (DE)
- University of Cologne (DE)
- Justus-Liebig-Universität Gießen (DE)
- Heidelberg University (DE)
- Universitätsmedizin Greifswald (DE)
- Eppendorf (Germany) (DE)
- University Hospital Heidelberg (DE)
- University Hospital Regensburg (DE)
- Medizinische Hochschule Hannover (DE)
- Löwenstein Medical (Germany) (DE)
- Pauls Stradiņš Clinical University Hospital (LV)
- Zimmer Biomet (Germany) (DE)
- John Paul II Hospital (PL)
- Medical Mission Institute (DE)
- Amsterdam Neuroscience (NL)
- University Medical Center Hamburg-Eppendorf (DE)
- Janssen (Germany) (DE)
- German Center for Lung Research (DE)
- Cardiovascular Research Center (BR)
- Universities of Giessen and Marburg Lung Center (DE)
- GWT-TUD (Germany) (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Amsterdam University Medical Centers (NL)
- University Hospital Carl Gustav Carus (DE)
- Imperial College London (GB)
- University of Regensburg (DE)
- Technische Universität Dresden (DE)
- Vrije Universiteit Amsterdam (NL)
- KU Leuven (BE)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1002/ehf2.15254
- Citations
- 4
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- United Therapeutics Corporation
- Acceleron
- Bayer HealthCare
- Deutsche Forschungsgemeinschaft
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- KU Leuven
- Servier
- AOP Orphan
- Janssen Biotech
- Daiichi Sankyo Europe
- Actelion Pharmaceuticals
- Cilag